The Latest
-
Permission granted by Ira Spector SFA Therapeutics
ProfileA biotech CEO’s favorite ‘F’ word
At SFA Therapeutics, patients are the “focus” of Ira Spector’s approach to changing the course of autoimmune disease.
-
Fizkes/Shutterstock.com
Sponsored by LiveWorldBoost returns from social strategies with new channels and tactics
Emerging channels offer new ways to reach key targets and improve campaign ROI.
-
Permission granted by Gilead Sciences
Q&AGilead’s commercial chief on why 2023 will be a ‘coming out’ year
With a rapidly expanding oncology pipeline and a new approval in HIV, Johanna Mercier discusses Gilead’s quest to transform.
-
Justin Sullivan/Staff via Getty Images
With Twitter in flux, pharma is turning to alternative social spaces
Elon Musk’s takeover of Twitter has upended the ways pharma companies communicate with doctors online. Now new social strategies are emerging.
-
Mike Coppola via Getty Images
Economic crisis? J&J execs say that won’t stop them from hitting $60B target
The pharma giant's CEO Joaquin Duato and CFO Joseph Wolk showed that they're optimistic about reaching lofty goals despite hard economic times.
-
Permission granted by Lauren Lazar Calcium
Podcast
Woman of the Week: Dr. Lauren Lazar
As Calcium’s medical director, Lazar is leveraging next-generation innovation to create strategic connections between science and marketing for healthcare brands.
-
magicmine, iStock / Getty Images Plus via Getty Images
AstraZeneca’s newest asthma launch fills a gap as generics chip away at respiratory flagships
A longtime leader in the respiratory space, AstraZeneca has hammered another stake in the ground with its newest asthma treatment, Airsupra.
-
Stock via Getty Images
Report reveals murky picture of clinical trial diversity gains
Data discrepancies between study phases and indications could provide clues about why some trials have better racial and ethnic diversity than others.
-
Permission granted by Astellas
Q&AAlready on a roll in oncology, Astellas hunts for big wins in other areas
With two potential first-in-class drug launches on the horizon, and a budding gene therapy business, Astellas believes this year could be a major inflection point.
-
Bill Oxford via Getty Images
Drug price negotiations: 5 key dates to watch
As the CMS readies its new program for lowering drug costs, these are the moments that will matter most to pharma companies.
-
Permission granted by Bekki Brown
Q&A // First 90 DaysUBC crowns Bekki Brown as its new CEO with a clear mandate to grow
The first-time CEO is tapping into decades of operational expertise to help bring real-world data into the mainstream.
-
Carsten Koall via Getty Images
After ‘limping along,’ Novavax sees a path forward
With a new CEO and a long-term booster strategy, the company believes there’s plenty of room to grow in the COVID-19 vaccine space.
-
Sarah Silbiger/Getty Images via Getty Images
FDA’s 2022 drug approvals fall short of recent norms
The U.S. agency’s lower number of novel drug approvals followed several controversies surrounding a 2021 Alzheimer’s approval.
-
Permission granted by CytomX
Q&AA Moderna tie-up ushers in new era for CytomX
The antibody-focused company followed up a tough year with big partnerships to keep the ball rolling.
-
Permission granted by Talia Cohen-Solal WoW
Podcast
Woman of the Week: Genetika+’s Talia Cohen Solal
The CEO is aiming to build a “brain-in-a-dish” to treat all patients for better mental health outcomes.
-
Enes Evren via Getty Images
ProfilePro sports’ COVID protocols led to real-world data impacts for pharma
After years of pioneering new methods for using data and technology to improve patient health outcomes, IQVIA’s Christina Mack is on the cusp of a research revolution.
-
JuSun via Getty Images
The M&A hunt is on — here are the prime targets
Companies with advanced molecular therapies, oncology assets and obesity treatments could be fuel for a dealmaking fire this year.
-
Stock via Getty Images
OpinionHow biotechs can weather the market storm
Execs at JPM sound off on moves companies can make to survive the challenging market conditions.
-
iStock via Getty Images
Space — the next frontier in drug development
Merck, Bristol Myers Squibb and others are taking small R&D steps in space that could lead to giant leaps for patients.
-
iStock via Getty Images
Biopharma M&A may get the push it needs in 2023, but with a face lift
A flurry of recent deals has reinforced forecasts that the long drought is over — circumstances have changed though, and M&A may not be the same.
-
Permission granted by Hans Schambye
Q&A // Biotech SpotlightGalecto has identified a master switch to reduce fibroid formation
With expertise surrounding a natural family of proteins and enzymes that can lead to fibrosis, Galecto is exploring the potential to develop cancer treatments.
-
Permission granted by Claire Aldridge Form Bio
Podcast
Woman of the Week: Form Bio’s Claire Aldridge
The chief strategy officer of Form Bio is harnessing the new company’s computing power and bioinformatics to spur a genomic revolution.
-
iStock via Getty Images
Biotech SpotlightChinook Therapeutics nears the finish line in kidney disease
A company focused on kidney disease, Chinook is growing into a commercial outfit as its lead candidate approaches the market.
-
Nicolaus Czarnecki/Zuma Press/Newscom
Making MovesC-suite changes at Biogen, Bluebird, Novavax give insight into 2023 business plans
A breakdown of the most buzzworthy executive changes so far in the new year and how they’re causing ripples in the life sciences industry.
-
Stock via Getty Images
Q&A // Biotech SpotlightGracell Biotechnologies’ quest to unlock the CAR-T bottleneck
The biotech hopes to upend the CAR-T category by cutting manufacturing from weeks to hours and developing a first-line cell therapy.
-
grapix via Getty Images
The kindred nature of martial arts and drug development
How the IRLAB Therapeutics CEO is guiding the company in its development of potentially groundbreaking Parkinson’s disease treatments.
